Clinical Trials

120 enrolled

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma

NCT06955169 2026-04-21

MOMENTUM-1

153 enrolled

Meningioma

NCT05749588 2026-04-16

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

120 enrolled

Triple Negative Breast Neoplasms

NCT04485559 2026-04-13

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Phase 1 Suspended

50 enrolled

Glioma

NCT07340541 2026-04-13

EVOLVE-BDT

700 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01167530 2026-04-06

RAD001

Phase 1 Completed

26 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06382948 2026-04-03

ADELA

Phase 3 Recruiting

240 enrolled

Phase 1 Active not recruiting

Advanced Breast Cancer

NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

29 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03950609 2026-03-19

Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors

Phase 2 Not yet recruiting

36 enrolled

EndocrineNET

Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1

NCT07477548 2026-03-17

A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies

67 enrolled

Arteriovenous Malformations, Hemangioendothelioma, Hemangioma, Lymphangioma, Nevus, Vascular Malformations

NCT05918302 2026-03-06

LEVEL

Phase 3 Recruiting

120 enrolled

EndocrineNET

Thymus Neoplasms, Neuroendocrine Tumors

NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Phase 1/2 Not yet recruiting

90 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT07435584 2026-02-27

EVER-RECODE

38 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Phase 4 Not yet recruiting

80 enrolled

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

NCT04199026 2026-02-19

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Phase NA Recruiting

20 enrolled

Sarcoma

NCT02397083 2026-02-13

LEVER

Phase 3 Not yet recruiting

102 enrolled

Gynecologic

Endometrial Hyperplasia

NCT07407517 2026-02-12

POLARIS

904 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

35 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

90 enrolled

Gynecologic

Endometrial Neoplasms

NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 18 charts

Breast Neoplasms

NCT05476939 2026-02-05

BIOMEDE 2

Phase 3 Recruiting

433 enrolled

Diffuse Intrinsic Pontine Glioma

NCT01217931 2026-01-30

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial